Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 Article Swipe
Rana Shami
,
Roberto Salgado
,
A. Bardia
,
G. Curigliano
,
Xichun Hu
,
Rebecca Dent
,
J-Y Pierga
,
Junji Tsurutani
,
Hans Wildiers
,
Giuseppina Rosaria Rita Ricciardi
,
Caterina Marchiò
,
Frédérique Penault‐Llorca
,
Catherine Bor-Angelier
,
Melissa Manoogian
,
Samuel J. E. Lucas
,
Matthew T. Olson
,
Xu Liu
,
Paula Toro
,
Amanda F. Baker
,
Quan Fang
,
Jialin Su
,
Anne D. Yoder
,
A. Andrzejuk-Cwik
,
Annie Darilay
,
Takayuki Matsuo
,
Frances M. Jones
,
Giuseppe Viale
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105310
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2025.105310
For patients with HER2 IHC 0 mBC, rescoring and/or retesting with the Roche HER2 4B5 assay is encouraged to determine eligibility for T-DXd.
Related Topics To Compare & Contrast
Concepts
Trastuzumab
Destiny (ISS module)
Internal medicine
Medicine
Engineering
Breast cancer
Cancer
Aerospace engineering
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.esmoop.2025.105310
- https://www.esmoopen.com/action/showPdf?pii=S2059702925011792
- OA Status
- gold
- Cited By
- 3
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411157652
All OpenAlex metadata
Raw OpenAlex JSON
No additional metadata available.